Researcher
Christine Desmedt
- Disciplines:Oncology
Affiliations
- Laboratory for Translational Breast Cancer Research (Division)
Responsible
From1 Oct 2018 → Today - Laboratory for Translational Breast Cancer Research (Division)
Member
From1 Oct 2018 → Today - Department of Oncology (Department)
Member
From1 Oct 2018 → 25 Dec 2018
Projects
1 - 10 of 23
- Atlas of therapeutic targets in metastatic breast cancer.From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- MetLob: A post-mortem tissue donation study dedicated to Metastatic Lobular breast cancerFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Impact of adiposity and lifestyle on breast cancer biology and treatment response.From7 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Histopathological heterogeneity of metastatic breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical and molecular heterogeneity of triple-negative breast cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of the tumor microenvironment of breast cancer metastasesFrom11 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- LIQUIDEVO: Unravelling breast cancer heterogeneity, progression and treatment resistance in the context of a rapid post-mortem institutional tissue donation program using phylogenetic reconstruction algorithms and an Open Science approach.From1 Oct 2021 → TodayFunding: FWO senior postdoctoral fellowship
- Facing Adiposity in personalizing Treatment of Breast Cancer PatientsFrom1 Mar 2021 → TodayFunding: H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
- Clinical, experimental and molecular characterization of liver metastases from breast cancer patients.From1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 115
- Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast(2022)
Authors: Liliana Sokol, Maxim De Schepper, Edoardo Isnaldi, Anh-Co Truong, François Richard, Ann Smeets, Ines Nevelsteen, Birgit Weynand, Christine Desmedt, Patrick Neven, et al.
- The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.(2022)
Authors: Edoardo Isnaldi, François Richard, Maxim De Schepper, Sophia Leduc, Tatjana Geukens, Karen Van Baelen, Ha Linh Nguyen, Beppe Floris, Christine Desmedt
Pages: 90 - The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer(2022)
Authors: Edoardo Isnaldi, François Richard, Maxim De Schepper, Sophia Leduc, Tatjana Geukens, Karen Van Baelen, Ha Linh Nguyen, Beppe Floris, Christine Desmedt
- Timing evolution of lobular breast cancer through phylogenetic analysis(2022)
Authors: Bram Boeckx, Diether Lambrechts, Christine Desmedt
- Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer(2022)
Authors: Karen Van Baelen, Tatjana Geukens, François Richard, Chantal Van Ongeval, Maxim De Schepper, Edoardo Isnaldi, Ines Nevelsteen, Ann Smeets, Hans Wildiers, Beppe Floris, et al.
Pages: 769 - 785 - ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast(2022)
Authors: Lieveke Ameye, Patrick Neven, Christine Desmedt
Pages: 2381 - 2392 - Trop-2 expression in triple-negative breast cancer according to histological subtype: correlations with tumor infiltrating lymphocytes (TILs) and survival(2022)
Authors: Hava Izci, Annouschka Laenen, Hans Wildiers, Christine Desmedt, Patrick Neven, Beppe Floris
- Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial(2022)
Authors: François Richard, Christine Desmedt
Pages: 308 - 318 - Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer (vol 41, pg 2932, 2022)(2022)
Authors: François Richard, Christine Desmedt
Pages: 3507 - 3509 - Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer(2022)
Authors: François Richard, Christine Desmedt
Pages: 2932 - 2944